Hematology & Oncology Doctors in Fairfield, OH Accepting Medicare

5 Hematology & Oncology doctors found. Showing 1 - 5

Dr. Prasad R Kudalkar, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3050 Mack Rd Ste 300, Fairfield, OH 45014 Phone: 513-751-2273    Fax: 513-751-1840

Dr. Paula F Weisenberger, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3050 Mack Rd, Ste 300, Fairfield, OH 45014 Phone: 513-682-4800    Fax: 513-682-4807

Edward J Crane, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3050 Mack Rd, Ste 300, Fairfield, OH 45014 Phone: 513-751-2273    Fax: 513-751-1840

Dr. Nicholas Brand Pleat, DO Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3050 Mack Rd, Fairfield, OH 45014 Phone: 513-751-2273

Jayadev Reddy Mettu, M.B.B.S Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3050 Mack Rd Ste 300, Fairfield, OH 45014 Phone: 513-751-2273    Fax: 513-751-1840

News Archive

Maintaining high-quality CT colonography while reducing radiation dose is possible, finds study

A new study by a Rhode Island Hospital researcher has found it's possible to maintain high-quality CT colonography diagnostic images while reducing the radiation dose.

Novel immunotherapy approach may offer therapeutic advantages for melanoma

In a new study led by Yale Cancer Center, researchers have advanced a tumor-targeting and cell penetrating antibody that can deliver payloads to stimulate an immune response to help treat melanoma.

Potential toxicity of zinc nanoparticles in sunscreen products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death. Their study is in ACS' Chemical Research in Toxicology, a monthly journal.

Gilead sues Lupin over Ranexa patent infringement

Gilead Sciences, Inc. today announced that it has filed a lawsuit in U.S. District Court in New Jersey against Lupin Limited for infringement against Gilead's patents for Ranexa® (ranolazine extended-release tablets). The lawsuit is based on an Abbreviated New Drug Application filed by Lupin, which seeks approval to manufacture and market a generic version of Ranexa before the expiration of Gilead's Ranexa patents.

Read more Medical News

› Verified 6 days ago